omeprazole has been researched along with Aging in 21 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind parallel-group study, 98 patients with symptomatic duodenal ulcer received omeprazole 20 mg o." | 9.06 | Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Opus (Omeprazole Peptic Ulcer Study) Research Group. ( Bate, CM; Crowe, JP; Peers, EM; Richardson, PD; Wilkinson, SP; Willoughby, CP, 1989) |
| "In this study, we compared the effects of cimetidine and omeprazole on the healing of acetic acid-induced gastric ulcers in 8-, 48-, and 96-week-old rats." | 7.71 | Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. ( Ishihara, M; Ito, M, 2002) |
| "The effect of omeprazole on acid secretion and gastrin levels has been investigated in 10 elderly duodenal ulcer patients in remission." | 7.68 | Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin. ( Cederberg, C; Lind, T; Olausson, M; Olbe, L, 1991) |
| " The mean hepatic clearances determined by in silico fitting for individual pharmacokinetic models of warfarin and midazolam in the aged group were, respectively, 23% and 56% smaller than those for the young group." | 5.48 | Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. ( Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H, 2018) |
| " Pharmacokinetic parameters were obtained by noncompartmental analysis." | 5.33 | The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ( Ishizawa, Y; Sasaki, M; Takahata, T; Tateishi, T; Yasui-Furukori, N, 2005) |
| "In a double-blind parallel-group study, 98 patients with symptomatic duodenal ulcer received omeprazole 20 mg o." | 5.06 | Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Opus (Omeprazole Peptic Ulcer Study) Research Group. ( Bate, CM; Crowe, JP; Peers, EM; Richardson, PD; Wilkinson, SP; Willoughby, CP, 1989) |
| "In this study, we compared the effects of cimetidine and omeprazole on the healing of acetic acid-induced gastric ulcers in 8-, 48-, and 96-week-old rats." | 3.71 | Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. ( Ishihara, M; Ito, M, 2002) |
| "The effect of omeprazole on acid secretion and gastrin levels has been investigated in 10 elderly duodenal ulcer patients in remission." | 3.68 | Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin. ( Cederberg, C; Lind, T; Olausson, M; Olbe, L, 1991) |
| " No studies have yet compared the effects of different dosages of clarithromycin in combination with a proton pump inhibitor and amoxicillin in elderly patients." | 2.70 | Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ( Bozzola, L; Di Mario, F; Franceschi, M; Leandro, G; Pilotto, A; Rassu, M; Soffiati, G; Valerio, G, 2001) |
| "25 L/min) and a prolongation of the mean elimination half-life from 0." | 2.67 | Pharmacokinetic study of omeprazole in elderly healthy volunteers. ( Andersson, T; Landahl, S; Larsson, M; Lernfeldt, B; Lundborg, P; Regårdh, CG; Sixt, E; Skånberg, I, 1992) |
| " The substance has an absolute bioavailability upon oral administration of approximately 52% which is robust against food intake or administration of antacids." | 2.41 | Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. ( Fuhr, U; Jetter, A, 2002) |
| " Mean plasma elimination half-life (t1/2) is between 1." | 2.39 | Clinical pharmacokinetics of lansoprazole. ( Flouvat, B; Landes, BD; Petite, JP, 1995) |
| "2." | 2.39 | Pathophysiological effects of long-term acid suppression in man. ( Arnold, R; Bardhan, KD; Cattan, D; Klinkenberg-Knol, E; Maton, PN; McCloy, RF; Riddell, RH; Sipponen, P; Walan, A, 1995) |
| " If two drugs of the same class have a similar dose-efficacy profile, then the favourable/unfavourable balance of the pharmacokinetic characteristics of the drugs may determine the drug of choice." | 2.39 | Pharmacokinetics--a relevant factor for the choice of a drug? ( Benet, LZ; Zech, K, 1994) |
| " The mean hepatic clearances determined by in silico fitting for individual pharmacokinetic models of warfarin and midazolam in the aged group were, respectively, 23% and 56% smaller than those for the young group." | 1.48 | Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. ( Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H, 2018) |
| " Pharmacokinetic parameters were obtained by noncompartmental analysis." | 1.33 | The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ( Ishizawa, Y; Sasaki, M; Takahata, T; Tateishi, T; Yasui-Furukori, N, 2005) |
| "Intramucosal cysts were found in biopsies of non-polypoid gastric body mucosa in 71." | 1.31 | Intramucosal cysts in the gastric body of patients with Zollinger-Ellison syndrome. ( Aprile, MR; Azzoni, C; Bordi, C; Gibril, F; Jensen, RT, 2000) |
| " Steady state plasma concentrations of lansoprazole were reached after 3 days of dosing with lansoprazole." | 1.29 | Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ( Cournot, A; Delhotal-Landes, B; Dellatolas, F; Flouvat, B, 1993) |
| "Omeprazole was rapidly cleared and possessed the characteristics of a high clearance drug; insignificant amounts of 14C-omeprazole were excreted by the kidneys, though metabolites were excreted very rapidly." | 1.27 | Pharmacokinetics and metabolism of omeprazole in man. ( Regårdh, CG, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 10 (47.62) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toda, A | 1 |
| Uehara, S | 1 |
| Inoue, T | 1 |
| Utoh, M | 1 |
| Kusama, T | 1 |
| Shimizu, M | 1 |
| Uno, Y | 1 |
| Mogi, M | 1 |
| Sasaki, E | 1 |
| Yamazaki, H | 1 |
| Tien, YC | 1 |
| Piekos, SC | 1 |
| Pope, C | 1 |
| Zhong, XB | 1 |
| Tsuji, S | 1 |
| Fuhr, U | 1 |
| Jetter, A | 1 |
| Flouvat, B | 2 |
| Delhotal-Landes, B | 1 |
| Cournot, A | 1 |
| Dellatolas, F | 1 |
| Ishizawa, Y | 1 |
| Yasui-Furukori, N | 1 |
| Takahata, T | 1 |
| Sasaki, M | 1 |
| Tateishi, T | 1 |
| Landes, BD | 1 |
| Petite, JP | 1 |
| McCloy, RF | 1 |
| Arnold, R | 1 |
| Bardhan, KD | 1 |
| Cattan, D | 1 |
| Klinkenberg-Knol, E | 1 |
| Maton, PN | 1 |
| Riddell, RH | 1 |
| Sipponen, P | 1 |
| Walan, A | 1 |
| Benet, LZ | 1 |
| Zech, K | 1 |
| Kakei, N | 2 |
| Ichinose, M | 2 |
| Tsukada, S | 2 |
| Tatematsu, M | 2 |
| Tezuka, N | 2 |
| Furihata, C | 1 |
| Yahagi, N | 2 |
| Matsushima, M | 2 |
| Miki, K | 1 |
| Kurokawa, K | 1 |
| Ishihama, S | 1 |
| Shimizu, Y | 1 |
| Kido, M | 1 |
| Pilotto, A | 3 |
| Franceschi, M | 3 |
| Di Mario, F | 3 |
| Leandro, G | 3 |
| Bozzola, L | 2 |
| Valerio, G | 3 |
| Grabau, BJ | 1 |
| Zavros, Y | 1 |
| Hardy, KJ | 1 |
| Shulkes, A | 1 |
| Aprile, MR | 1 |
| Azzoni, C | 1 |
| Gibril, F | 1 |
| Jensen, RT | 1 |
| Bordi, C | 1 |
| Battaglia, G | 1 |
| Germanà, B | 1 |
| Marin, R | 1 |
| Rassu, M | 1 |
| Soffiati, G | 1 |
| Ishihara, M | 1 |
| Ito, M | 1 |
| Landahl, S | 1 |
| Andersson, T | 1 |
| Larsson, M | 1 |
| Lernfeldt, B | 1 |
| Lundborg, P | 1 |
| Regårdh, CG | 2 |
| Sixt, E | 1 |
| Skånberg, I | 1 |
| Lind, T | 1 |
| Cederberg, C | 1 |
| Olausson, M | 1 |
| Olbe, L | 1 |
| Crowe, JP | 1 |
| Wilkinson, SP | 1 |
| Bate, CM | 1 |
| Willoughby, CP | 1 |
| Peers, EM | 1 |
| Richardson, PD | 1 |
5 reviews available for omeprazole and Aging
| Article | Year |
|---|---|
[Prevention and treatment of gastro-duodenal ulcers in elderly--from theory-based toward evidence-based].
Topics: Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Evidence-Based Medicine; Humans; Misoprostol; | 2002 |
Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aging; Anti-Ulcer Agents; Benzimidazoles; Biological | 2002 |
Clinical pharmacokinetics of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aging; Anti-Ulcer Agents; Drug Interactions; Gastrointestin | 1995 |
Pathophysiological effects of long-term acid suppression in man.
Topics: Aging; Anemia, Pernicious; Enterochromaffin Cells; Female; Gastric Acid; Histamine H2 Antagonists; H | 1995 |
Pharmacokinetics--a relevant factor for the choice of a drug?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aging; Benzimidazoles; Biological Ava | 1994 |
4 trials available for omeprazole and Aging
| Article | Year |
|---|---|
Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Aging; Amoxicillin; Anti-Bacterial Agent | 2000 |
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Aged, 80 and over; Aging; Amoxi | 2001 |
Pharmacokinetic study of omeprazole in elderly healthy volunteers.
Topics: Administration, Oral; Aged; Aging; Biological Availability; Dose-Response Relationship, Drug; Female | 1992 |
Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Opus (Omeprazole Peptic Ulcer Study) Research Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Cimetidine; Double-Blind Method; Duodenal Ulcer; | 1989 |
12 other studies available for omeprazole and Aging
| Article | Year |
|---|---|
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotyp | 2018 |
Phenobarbital Treatment at a Neonatal Age Results in Decreased Efficacy of Omeprazole in Adult Mice.
Topics: Aging; Animals; Animals, Newborn; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme System; | 2017 |
Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Aging; Area Under Curve; Dose-Resp | 1993 |
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Aging; Alleles; Analysis of | 2005 |
Effects of omeprazole on gastric mucosal growth and differentiation in developing rat.
Topics: Aging; Animals; Cathepsin E; Cathepsins; Cell Differentiation; Cell Division; Gastric Mucosa; Gastri | 1993 |
Effects of omeprazole, a proton pump inhibitor, on pepsinogen-producing cells, with special reference to neonatal development.
Topics: Aging; Animals; Animals, Newborn; Blotting, Northern; Body Weight; Enzyme Inhibitors; Gastric Juice; | 1995 |
The long-term clinical outcome of elderly patients with Helicobacter pylori-associated peptic ulcer disease.
Topics: Aged; Aging; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastritis; | 1998 |
Developmental regulation of gastric somatostatin secretion in the sheep.
Topics: Aging; Animals; Animals, Newborn; Drug Combinations; Embryonic and Fetal Development; Female; Fetus; | 1999 |
Intramucosal cysts in the gastric body of patients with Zollinger-Ellison syndrome.
Topics: Adult; Aged; Aged, 80 and over; Aging; Biopsy; Cell Division; Cysts; Enterochromaffin Cells; Female; | 2000 |
Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole.
Topics: Aging; Animals; Cimetidine; Gastrins; Male; Omeprazole; Rats; Rats, Wistar; Stomach Ulcer | 2002 |
Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin.
Topics: Aged; Aging; Dose-Response Relationship, Drug; Duodenal Ulcer; Gastric Acid; Gastrins; Humans; Male; | 1991 |
Pharmacokinetics and metabolism of omeprazole in man.
Topics: Administration, Oral; Aged; Aging; Anti-Ulcer Agents; Benzimidazoles; Diazepam; Dose-Response Relati | 1986 |